Information Provided By:
Fly News Breaks for November 12, 2015
SHPG, VRX, SGYP
Nov 12, 2015 | 08:02 EDT
Canaccord still views Synergy Pharmaceuticals (SGYP) as a saleable asset, with Valeant (VRX) or Shire (SHPG) seen as the most obvious buyers. The firm also sees the cost of the launch of plecanatide as lower than expected and sees no need for the company to raise capital until at least the end of 2016. Canaccord reiterated its Buy rating and $19 price target on Synergy Pharmaceuticals shares.
News For SGYP;VRX;SHPG From the Last 2 Days
There are no results for your query SGYP;VRX;SHPG